Tech Mahindra, NVIDIA Partner for AI-Powered Drug Safety Innovation

In a tactical initiative to improve drug safety oversight, Tech Mahindra, a worldwide frontrunner in technology consulting and digital services, has revealed an AI-based pharmacovigilance (PV) solution utilizing NVIDIA AI software. The solution seeks to transform pharmacovigilance processes by utilizing agentic AI and automation to enhance precision, speed, and effectiveness while addressing industry issues such as manual delays and excessive data.

Leveraging Tech Mahindra’s TENO framework along with NVIDIA AI Enterprise software, the solution integrates NVIDIA NeMo, NVIDIA NIM microservices, and NVIDIA AI Blueprints to automate case intake, data transformation, and quality control, guaranteeing regulatory compliance and smooth PV operations. AI agents driven by LLM autonomously categorize, rank, and validate pharmacovigilance emails, greatly minimizing human mistakes.

“As the pharmaceutical industry navigates volumes of data during trials and post-launch, our collaboration with NVIDIA leverages generative AI and multi-agent systems to streamline pharmacovigilance processes,” said Nikhil Malhotra, Chief Innovation Officer, Tech Mahindra.

The AI-driven PV solution can reduce turnaround times by up to 40%, enhance data accuracy by 30%, and cut operational costs by 25%, ensuring faster regulatory compliance and risk mitigation. “AI is ideal for monitoring medicines throughout their lifecycle to support safety,” said John Fanelli, Vice President, Enterprise Software, NVIDIA.

By integrating agentic AI-driven intelligence, Tech Mahindra and NVIDIA aim to transform pharmacovigilance from reactive to predictive, ensuring better patient outcomes and global drug safety.